The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Scotland has become the first part of the UK to screen babies for spinal muscular atrophy, a rare condition that causes ...

It's well known that spaceflight causes muscle atrophy and other biological changes in reduced gravity, and especially in ...

Spinal Muscular Atrophy (SMA) causes progressive muscle weakness and, without treatment, can limit life expectancy to just ...

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was ...

But for Brooklyn, who lives with spinal muscular atrophy, or SMA, a rare genetic condition that affects muscle strength and ...

Parents have said new screening tests for Spinal muscular atrophy are a "game-changer".

Roche (RHHBF) stock is in focus as the company halts mid-stage trials for emugrobart in rare neuromuscular diseases but ...

Scotland becomes first part of UK to screen babies for rare muscle disease - All parents will now be offered spinal muscular ...